HSCS vs. POAI, NAOV, GRAY, IBIO, UPC, SBFM, IMCC, NURO, ENVB, and TTNP
Should you be buying Heart Test Laboratories stock or one of its competitors? The main competitors of Heart Test Laboratories include Predictive Oncology (POAI), NanoVibronix (NAOV), Graybug Vision (GRAY), iBio (IBIO), Universe Pharmaceuticals (UPC), Sunshine Biopharma (SBFM), IM Cannabis (IMCC), NeuroMetrix (NURO), Enveric Biosciences (ENVB), and Titan Pharmaceuticals (TTNP). These companies are all part of the "medical" sector.
Predictive Oncology (NASDAQ:POAI) and Heart Test Laboratories (NASDAQ:HSCS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment.
In the previous week, Predictive Oncology had 1 more articles in the media than Heart Test Laboratories. MarketBeat recorded 2 mentions for Predictive Oncology and 1 mentions for Heart Test Laboratories. Heart Test Laboratories' average media sentiment score of 0.21 beat Predictive Oncology's score of -0.01 indicating that Predictive Oncology is being referred to more favorably in the media.
9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 17.2% of Heart Test Laboratories shares are held by institutional investors. 3.4% of Predictive Oncology shares are held by insiders. Comparatively, 2.7% of Heart Test Laboratories shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Predictive Oncology received 145 more outperform votes than Heart Test Laboratories when rated by MarketBeat users. However, 75.00% of users gave Heart Test Laboratories an outperform vote while only 64.35% of users gave Predictive Oncology an outperform vote.
Heart Test Laboratories has lower revenue, but higher earnings than Predictive Oncology. Predictive Oncology is trading at a lower price-to-earnings ratio than Heart Test Laboratories, indicating that it is currently the more affordable of the two stocks.
Predictive Oncology has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Heart Test Laboratories has a beta of 3.44, meaning that its share price is 244% more volatile than the S&P 500.
Heart Test Laboratories has a net margin of 0.00% compared to Heart Test Laboratories' net margin of -785.62%. Heart Test Laboratories' return on equity of -104.21% beat Predictive Oncology's return on equity.
Summary
Predictive Oncology and Heart Test Laboratories tied by winning 7 of the 14 factors compared between the two stocks.
Get Heart Test Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSCS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Heart Test Laboratories Competitors List
Related Companies and Tools
